A Phase 3 interventional study of Placebo and Belimumab 1 mg/kg in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc.. Completed at 92 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-12.
Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 11 in phase 3, and was the 3rd registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 865 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc. is the lead sponsor of 23 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2007, is one of 10 in phase 3, and was the 3rd registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
Belimumab 1 mg/kg
Drug: Belimumab 1 mg/kg
Belimumab 10 mg/kg
Drug: Belimumab 10 mg/kg
Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Drug page: Belimumab
Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Also known as: BENLYSTA™ (formerly LymphoStat-B™)
Drug page: Belimumab
Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Also known as: BENLYSTA™ (formerly LymphoStat-B™)
SLE Responder Index (SRI) Response Rate at Week 52
Percentage of subjects with a ≥ 4 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of \< 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline. SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. PGA is a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E).
Time frame: Baseline, 52 weeks
Percent of Subjects With a ≥ 4 Point Reduction From Baseline in SELENA SLEDAI Score at Wk 52.
Time frame: Baseline, 52 weeks
Mean Change in Physician's Global Assessment (PGA) at Wk 24.
The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.
Time frame: Baseline, 24 weeks
Mean Change From Baseline in Medical Outcomes 36-Item Short Form Health Survey (SF-36) Physical Component Summary Score (PCS) at Wk 24.
The SF-36 is a generic health related quality of life (HRQOL) measurement. The survey includes 36 questions grouped to 8 domains and 2 summary measures (physical and mental health component, PCS and MCS, respectively) assessing HRQOL. Responses are scored according to the SF-36v2™ manual. A score is calculated for each SF-36 domain based on the patient's response to each question within it. This is then transformed to a scale ranging from 0 (worst) to 100 (best) points. The PCS is norm-based where the mean=50 and standard deviation (SD)=10. Higher scores represent better physical health.
Time frame: Baseline, 24 weeks
Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline to ≤ 7.5 mg/Day During Weeks 40 Through 52
Time frame: Baseline, Weeks 40 through 52
Adverse Events (AE) Overview
SEE ALSO ADVERSE EVENTS RESULTS SECTION
Time frame: Up to 56 Weeks
| Milestone | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg |
|---|---|---|---|
| Started | 287 | 288 | 290 |
| Completed | 226 | 240 | 241 |
| Not completed | 61 | 48 | 49 |
| Withdrew: Withdrawal by subject | 7 | 6 | 3 |
| Withdrew: Adverse event | 19 | 16 | 15 |
| Withdrew: Lack of efficacy | 16 | 12 | 12 |
| Withdrew: Lack of compliance | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 4 | 6 | 3 |
| Withdrew: Protocol violation | 7 | 2 | 3 |
| Withdrew: Physician decision | 3 | 2 | 3 |
| Withdrew: Other | 4 | 3 | 9 |
Percentage of subjects with a ≥ 4 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of \< 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline. SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. PGA is a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E).
| Percentage of participants | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg |
|---|---|---|---|
| SLE Responder Index (SRI) Response Rate at Week 52 | 43.6 | 51.4 | 57.6 |
| Percentage of participants | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg |
|---|---|---|---|
| Percent of Subjects With a ≥ 4 Point Reduction From Baseline in SELENA SLEDAI Score at Wk 52. | 46.0 | 53.1 | 58.3 |
The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.
| Scores on a 3-point scale | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg |
|---|---|---|---|
| Mean Change in Physician's Global Assessment (PGA) at Wk 24. | -0.39 ± 0.03 | -0.44 ± 0.03 | -0.54 ± 0.03 |
The SF-36 is a generic health related quality of life (HRQOL) measurement. The survey includes 36 questions grouped to 8 domains and 2 summary measures (physical and mental health component, PCS and MCS, respectively) assessing HRQOL. Responses are scored according to the SF-36v2™ manual. A score is calculated for each SF-36 domain based on the patient's response to each question within it. This is then transformed to a scale ranging from 0 (worst) to 100 (best) points. The PCS is norm-based where the mean=50 and standard deviation (SD)=10. Higher scores represent better physical health.
| Scores on a scale | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg |
|---|---|---|---|
| Mean Change From Baseline in Medical Outcomes 36-Item Short Form Health Survey (SF-36) Physical Component Summary Score (PCS) at Wk 24. | 3.64 ± 0.42 | 3.65 ± 0.43 | 3.58 ± 0.46 |
| Percentage of participants | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg |
|---|---|---|---|
| Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline to ≤ 7.5 mg/Day During Weeks 40 Through 52 | 12.0 (0 to 0) | 20.6 (1.08 to 3.31) | 18.6 (0.99 to 3.08) |
SEE ALSO ADVERSE EVENTS RESULTS SECTION
| Percentage of participants | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg |
|---|---|---|---|
| Percent of patients with at least 1 AE | 91.6 | 91.7 | 91.7 |
| Percent of patients with at least 1 Serious AE | 12.5 | 16.3 | 14.1 |
| Percent of patients with an AE resulting in death | 1.0 | 0.7 | 1.4 |
Collected over Up to 56 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 36/287 (12.5%) | 222/287 (77.4%) |
| Belimumab 1 mg/kg | — | 47/288 (16.3%) | 219/288 (76%) |
| Belimumab 10 mg/kg | — | 41/290 (14.1%) | 223/290 (76.9%) |
| Event | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg |
|---|---|---|---|
| PneumoniaInfections and infestations | 5/287 | 1/288 | 1/290 |
| PyrexiaGeneral disorders | 1/287 | 4/288 | 4/290 |
| CellulitisInfections and infestations | 1/287 | 4/288 | 1/290 |
| Urinary tract infectionInfections and infestations | 2/287 | 4/288 | 2/290 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/287 | 3/288 | 1/290 |
| Lupus nephritisRenal and urinary disorders | 0/287 | 3/288 | 3/290 |
| SLE arthritisMusculoskeletal and connective tissue disorders | 1/287 | 0/288 | 3/290 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/287 | 1/288 | 3/290 |
| Gastroenteritis bacterialInfections and infestations | 2/287 | 0/288 | 0/290 |
| Herpes zosterInfections and infestations | 2/287 | 2/288 | 1/290 |
| Event | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg |
|---|---|---|---|
| HeadacheNervous system disorders | 75/287 | 58/288 | 66/290 |
| Upper respiratory tract infectionInfections and infestations | 47/287 | 41/288 | 36/290 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 33/287 | 21/288 | 32/290 |
| InfluenzaInfections and infestations | 25/287 | 22/288 | 33/290 |
| NauseaGastrointestinal disorders | 31/287 | 16/288 | 23/290 |
| HypertensionVascular disorders | 30/287 | 24/288 | 17/290 |
| NasopharyngitisInfections and infestations | 23/287 | 30/288 | 20/290 |
| DiarrhoeaGastrointestinal disorders | 19/287 | 28/288 | 30/290 |
| Urinary tract infectionInfections and infestations | 24/287 | 27/288 | 26/290 |
| Back painMusculoskeletal and connective tissue disorders | 25/287 | 25/288 | 19/290 |
| Age, Continuous(years) | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg | Total |
|---|---|---|---|---|
| Mean | 36.2 ± 11.8 | 35.0 ± 10.6 | 35.4 ± 10.8 | 35.5 ± 11.1 |
| Age, Customized(participants) | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg | Total |
|---|---|---|---|---|
| ≤ 45 years | 225 | 236 | 236 | 697 |
| Between 45 and 65 years | 57 | 48 | 52 | 157 |
| ≥ 65 years | 5 | 4 | 2 | 11 |
| Gender(Participants) | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg | Total |
|---|---|---|---|---|
| Female | 270 | 271 | 280 | 821 |
| Male | 17 | 17 | 10 | 44 |
| Region of Enrollment(participants) | Placebo | Belimumab 1 mg/kg | Belimumab 10 mg/kg | Total |
|---|---|---|---|---|
| Europe | 33 | 34 | 31 | 98 |
| South America | 145 | 143 | 140 | 428 |
| Southeast Asia | 103 | 106 | 115 | 324 |
| Australia | 6 | 5 | 4 | 15 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of May 2007, a primary completion of May 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years after primary completion. A results delay was requested in Sep 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →